Mechanistically, VEGF-C can provide melanocyte-specific protein tyrosine kinase clearance and cross-presentation of antigens through LEC to induce CD8+ T cell dysfunction, resulting in tumor cell immune tolerance [78, 80, 81]. The gene discussed is CD8A; the disease is neoplasm.